A Phase II Trial of O6-Benzylguanine (NSC 637037) and BCNU (Carmustine) in Patients With Advanced Soft Tissue Sarcoma

Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically or cytologically confirmed recurrent, metastatic,
or locally advanced soft tissue sarcoma considered incurable by surgery or radiotherapy
Bidimensionally measurable disease At least 1 cm x 1 cm, with clearly defined margins on
CT scan, X-ray, or physical examination Located outside of radiation port or evidence of
progression within radiation port No CNS disease only No uncontrolled symptomatic brain
metastases regardless of other disease sites

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At
least 12 weeks Hematopoietic: WBC at least 3,000/mm3 Absolute neutrophil count at least
1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin normal unless due to
Gilbert's syndrome SGOT or SGPT no greater than 2 times upper limit of normal Renal:
Creatinine no greater than 1.5 mg/dL OR Creatinine clearance at least 60 mL/min Pulmonary:
DLCO at least 80% predicted Other: Not pregnant or nursing Negative pregnancy test Fertile
patients must use effective contraception No other concurrent significant underlying
medical or psychiatric illness (e.g., active infection) that would preclude study
treatment or exceptionally increase risk of toxicities No other prior malignancy within
the past 5 years except curatively treated nonmelanoma skin cancer, carcinoma in situ of
the cervix, or superficial bladder cancer

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
chemotherapy for metastatic disease At least 4 weeks since prior neoadjuvant and/or
adjuvant chemotherapy No other concurrent chemotherapy No concurrent investigational
antineoplastic drugs Endocrine therapy: Not specified Radiotherapy: See Disease
Characteristics At least 3 weeks since prior radiotherapy and recovered No concurrent
radiotherapy to any lesion Surgery: See Disease Characteristics